The purpose of this study is to investigate the effect of benfotiamine supplementation in
patients with diabetic nephropathy, and to determine whether it will slow down the
progression to end-stage renal disease (ESRD).
Phase:
Phase 4
Details
Lead Sponsor:
University Medical Center Groningen
Collaborators:
Isala Predictions Network Wörwag Pharma GmbH & Co. KG